Cost effectiveness and delivery study for future HIV vaccines
- 2 September 2005
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 19 (13) , w1-w6
- https://doi.org/10.1097/01.aids.0000181014.08127.a7
Abstract
Research teams from five countries, Brazil, China, Kenya, Peru and Thailand, have initiated a policy-maker survey on vaccine delivery, cost studies for future HIV vaccination programmes, and associated simulation modeling exercises analysing the relative cost-effectiveness of potential HIV vaccination strategies. The survey assesses challenges and opportunities for future country-level HIV vaccination strategies, providing data on the vaccine characteristics (e.g. vaccine efficacies for susceptibility, infectiousness and disease progression) and vaccination programme strategies to be considered in the cost-effectiveness modeling analyses. The study will provide decision-makers with modeling data on vaccination policy considerations that will assist in developing country-level capacities for future HIV vaccine policy adoption and effective delivery systems, and will help delineate the long-term financial requirements for sustainable HIV vaccination programmes. The WHO-UNAIDS HIV Vaccine Initiative and the collaborating researchers welcome comments or questions from policy makers, health professionals and other stakeholders in the public and private sectors about this effort to help advance policy and capacity related to future potential HIV vaccines.Keywords
This publication has 19 references indexed in Scilit:
- The Global Vaccination GapScience, 2004
- Prospects for an AIDS vaccine: three big questions, no easy answersThe Lancet Infectious Diseases, 2004
- Developing an AIDS Vaccine: Need, Uncertainty, HopeScience, 2004
- Drug resistance and adherence to HIV/AIDS antiretroviral treatmentAIDS, 2004
- Public health considerations for the use of a first generation HIV vaccine Report from a WHO-UNAIDS-CDC Consultation, Geneva, 20–21 November 2002AIDS, 2003
- On the analysis of viral load endpoints in HIV vaccine trialsStatistics in Medicine, 2003
- Estimation of ?needs? and ?probable uptake? for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study)Vaccine, 2003
- Can we reverse the HIV/AIDS pandemic with an expanded response?The Lancet, 2002
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Study Designs for Evaluating Different Efficacy and Effectiveness Aspects of VaccinesAmerican Journal of Epidemiology, 1997